vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $821.5M, roughly 1.6× Acadia Healthcare Company, Inc.). WEIBO Corp runs the higher net margin — 35.7% vs -143.3%, a 179.0% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 3.4%).
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
ACHC vs WB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $821.5M | $1.3B |
| Net Profit | $-1.2B | $458.3M |
| Gross Margin | — | — |
| Operating Margin | -142.4% | 29.1% |
| Net Margin | -143.3% | 35.7% |
| Revenue YoY | 6.1% | — |
| Net Profit YoY | -3710.4% | — |
| EPS (diluted) | $-12.98 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $821.5M | — | ||
| Q3 25 | $851.6M | $1.3B | ||
| Q2 25 | $869.2M | $841.7M | ||
| Q1 25 | $770.5M | $396.9M | ||
| Q4 24 | $774.2M | — | ||
| Q3 24 | $815.6M | $1.3B | ||
| Q2 24 | $796.0M | $833.4M | ||
| Q1 24 | $768.1M | $395.5M |
| Q4 25 | $-1.2B | — | ||
| Q3 25 | $36.2M | $458.3M | ||
| Q2 25 | $30.1M | $234.8M | ||
| Q1 25 | $8.4M | $108.1M | ||
| Q4 24 | $32.6M | — | ||
| Q3 24 | $68.1M | $297.4M | ||
| Q2 24 | $78.5M | $164.6M | ||
| Q1 24 | $76.4M | $51.1M |
| Q4 25 | -142.4% | — | ||
| Q3 25 | 4.7% | 29.1% | ||
| Q2 25 | 5.8% | 30.4% | ||
| Q1 25 | 1.7% | 27.8% | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 12.1% | 29.0% | ||
| Q2 24 | 13.4% | 28.2% | ||
| Q1 24 | 12.9% | 25.2% |
| Q4 25 | -143.3% | — | ||
| Q3 25 | 4.3% | 35.7% | ||
| Q2 25 | 3.5% | 27.9% | ||
| Q1 25 | 1.1% | 27.2% | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 8.4% | 22.9% | ||
| Q2 24 | 9.9% | 19.8% | ||
| Q1 24 | 9.9% | 12.9% |
| Q4 25 | $-12.98 | — | ||
| Q3 25 | $0.40 | — | ||
| Q2 25 | $0.33 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.36 | — | ||
| Q3 24 | $0.74 | — | ||
| Q2 24 | $0.85 | — | ||
| Q1 24 | $0.83 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.2M | $1.1B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $1.9B | $3.9B |
| Total Assets | $5.5B | $6.9B |
| Debt / EquityLower = less leverage | 1.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $133.2M | — | ||
| Q3 25 | $118.7M | $1.1B | ||
| Q2 25 | $131.4M | $1.2B | ||
| Q1 25 | $91.2M | $1.2B | ||
| Q4 24 | $76.3M | — | ||
| Q3 24 | $82.1M | — | ||
| Q2 24 | $77.2M | $1.9B | ||
| Q1 24 | $77.3M | $2.1B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $1.9B | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $3.1B | $3.9B | ||
| Q2 25 | $3.1B | $3.6B | ||
| Q1 25 | $3.0B | $3.5B | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.0B | — | ||
| Q2 24 | $3.0B | $3.4B | ||
| Q1 24 | $2.9B | $3.3B |
| Q4 25 | $5.5B | — | ||
| Q3 25 | $6.4B | $6.9B | ||
| Q2 25 | $6.3B | $6.5B | ||
| Q1 25 | $6.1B | $6.7B | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $5.7B | $7.1B | ||
| Q1 24 | $5.5B | $7.3B |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-86.3M | — |
| Free Cash FlowOCF − Capex | $-179.5M | — |
| FCF MarginFCF / Revenue | -21.8% | — |
| Capex IntensityCapex / Revenue | 11.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-439.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-86.3M | — | ||
| Q3 25 | $73.2M | — | ||
| Q2 25 | $133.5M | — | ||
| Q1 25 | $11.5M | — | ||
| Q4 24 | $116.7M | — | ||
| Q3 24 | $163.1M | — | ||
| Q2 24 | $171.1M | — | ||
| Q1 24 | $-321.3M | — |
| Q4 25 | $-179.5M | — | ||
| Q3 25 | $-63.0M | — | ||
| Q2 25 | $-34.2M | — | ||
| Q1 25 | $-163.2M | — | ||
| Q4 24 | $-86.8M | — | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $16.9M | — | ||
| Q1 24 | $-463.7M | — |
| Q4 25 | -21.8% | — | ||
| Q3 25 | -7.4% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | -11.2% | — | ||
| Q3 24 | -3.3% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -60.4% | — |
| Q4 25 | 11.3% | — | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | 19.3% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 19.4% | — | ||
| Q1 24 | 18.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 2.39× | — | ||
| Q2 24 | 2.18× | — | ||
| Q1 24 | -4.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $451.2M | 55% |
| Comprehensive Treatment Centers | $144.2M | 18% |
| Medicare | $113.7M | 14% |
| Residential Treatment Centers | $89.7M | 11% |
| Self Payor | $16.1M | 2% |
| Other Payor | $10.7M | 1% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
